trending Market Intelligence /marketintelligence/en/news-insights/trending/4ds1wboaisc1zwgpc7ehfq2 content esgSubNav
In This List

ASCO conference: MEI Pharma blood cancer drug shows activity in study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ASCO conference: MEI Pharma blood cancer drug shows activity in study

MEI Pharma Inc. said its ME-401 drug showed anticancer activity in patients with different types of lymphoma in a phase 1b study, according to data presented at the 2018 American Society of Clinical Oncology meeting.

The study showed that 90% of the 30 evaluable patients with follicular lymphoma whose disease returned or did not respond to treatments, chronic lymphocytic lymphoma, or small lymphocytic lymphoma saw a reduction in their disease.

The San Diego-based company intends to conduct another study of the drug later in 2018.

The 2018 American Society of Clinical Oncology meeting is expected to bring together more than 32,000 professionals from all over the world, with more than 2,500 study abstracts to be presented on-site and an additional 3,350 abstracts to be published online.